PHILOGEN SRL has a total of 29 patent applications. Its first patent ever was published in 1997. It filed its patents most often in Australia, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are CENTRE HOSPITALIER REGIONAL UNIV DE MONTPELLIER, INATHERYS and ALFA LAVAL AGRI INTERNAT AKTIE.
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Measuring microorganism processes | |
#5 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Zardi Luciano | 21 |
#2 | Neri Dario | 18 |
#3 | Carnemolla Barbara | 16 |
#4 | Borsi Laura | 15 |
#5 | Castellani Patrizia | 13 |
#6 | Balza Enrica | 11 |
#7 | Pini Alessandro | 11 |
#8 | Siri Annalisa | 10 |
#9 | Neri Giovanni | 10 |
#10 | Winter Greg | 8 |
Publication | Filing date | Title |
---|---|---|
AU2006200762A1 | Compositions and methods for treatment of angiogenesis in pathological lesions | |
AU2193802A | Process for selecting anti-angiogenesis antibody fragments, anti-angiogenesis antibody fragments thus obtained and their use | |
AU8182401A | Methods for quantitative determination of b-fibronectin in biological fluids andtissues | |
WO0183816A2 | Method for detecting tumors | |
AU3947001A | Compositions and methods for treatment of angiogenesis in pathological lesions | |
CA2370666A1 | A tenascin-c isoform as a marker for neoplasias |